Evidence map›Paper›PMID 41933733›Full record

ArticleThe Journal of biological chemistry2026

Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3.

Mari Nakashima, Sandipan Mukherjee, Decha Pinkaew, Uttariya Pal, Jolanda van Hengel, Geert Berx, Ken Fujise

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mari NakashimaDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Sandipan MukherjeeDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Decha PinkaewDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Uttariya PalDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Jolanda van HengelDepartment of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Geert BerxDepartment of Biomedical Molecular Biology and Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Ken FujiseDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA. Electronic address: kfujise@uw.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fortilin, a 172 amino acid modulator protein that positively regulates survival and growth pathways, is one of the most abundantly expressed proteins in the heart, and its loss leads to lethal heart failure. While fortilin binds and protects catenin alpha-3 (CTNNA3)-a cardiomyocyte structural and survival protein-against degradation, its role in the transcriptional regulation of CTNNA3 has remained unknown. Here, we report that fortilin also promotes CTNNA3 transcription. Mechanistically, we found that fortilin specifically bound to the N-terminal region (amino acids 1-85) of myocyte enhancer factor 2C (MEF2C)-a transcription factor that drives CTNNA3 expression-but not to MEF2A, MEF2B, or MEF2D, as shown by microscale thermophoresis, proximity ligation assay, and in vitro and in vivo coimmunoprecipitation Western blot analyses. Molecular docking and site-directed mutagenesis identified a critical binding interface involving aspartic acid 25 of fortilin, whereby an aspartic acid 25-to-alanine mutation markedly weakened binding to MEF2C. In addition, fortilin protected MEF2C against ubiquitination and proteasomal degradation and promoted MEF2C serine 59 phosphorylation, a modification essential for its transcriptional activity, both in a binding-dependent manner. Loss of fortilin significantly impaired MEF2C binding to nuclear DNA, reduced CTNNA3 promoter-driven luciferase activity in an MEF2C-dependent fashion, and lowered RNA polymerase II occupancy on the CTNNA3 locus. These data suggest that fortilin is a previously unrecognized transcriptional cofactor of MEF2C. By stabilizing MEF2C and promoting its activating phosphorylation, fortilin enhances the transcription of CTNNA3 while simultaneously stabilizing CTNNA3 protein, thereby sustaining CTNNA3 expression and supporting myocardial structural integrity.

Indexed as

MEF2 Transcription FactorsTranscription, GeneticTumor Protein, Translationally-Controlled 1HumansPhosphorylationProtein BindingMEF2C protein, humanMEF2 Transcription FactorsTPT1 protein, humanTumor Protein, Translationally-Controlled 1alpha-T-cateninCTNNA3fortilinHRFMEF2Cphosphorylationprotein–protein interactionTCTPTPT1transcription

Identifiers

PMID41933733
PMCPMC13157077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.